Ironwood Pharmaceuticals | IRWD - Srodki Pieniężne I Ekwiwalent





Srodki Pieniężne I Ekwiwalent Zmiana Data
Acadia Pharmaceuticals USD 851.46M 31.77M 2026-03
Agios Pharmaceuticals USD 113.6M 24.47M 2026-03
Akebia Therapeutics USD 162.64M 22.2M 2026-03
Almirall EUR 337.77M 14.83M 2025-12
Alnylam Pharmaceuticals USD 1.71B 53.53M 2026-03
Amarin USD 131.06M 3.6M 2026-03
Ardelyx USD 31.21M 36.79M 2026-03
Astellas Pharma JPY 188.37B 8.51B 2025-03
AstraZeneca USD 7.56B 1.85B 2026-03
Charles River Laboratories USD 191.83M 21.94M 2026-03
Coherus Biosciences USD 88.88M 14.47M 2025-12
Emergent BioSolutions USD 111.7M 23.9M 2023-12
Esperion Therapeutics USD 156.16M 11.69M 2026-03
Halozyme Therapeutics USD 309.75M 175.93M 2026-03
Incyte USD 4.02B 435.22M 2026-03
Ironwood Pharmaceuticals USD 220.47M 5.01M 2026-03
Karyopharm Therapeutics USD 60.54M 22.87M 2025-12
Lexicon Pharmaceuticals USD 38.09M 3.76M 2026-03
MacroGenics USD 66.52M 9.3M 2026-03
Moderna USD 1.91B 687M 2026-03
Myriad Genetics USD 124.4M 25.2M 2026-03
Pacira USD 144.31M 14.24M 2026-03
PTC Therapeutics USD 833.99M 150.66M 2026-03
Puma Biotechnology USD 53.52M 1.14M 2025-09
Sarepta Therapeutics USD 464.45M 336.83M 2026-03
Takeda JPY 654.94B 26.55B 2025-12
Ultragenyx Pharmaceutical USD 175M 246M 2026-03
Vanda Pharmaceuticals USD 84.85M 14.83M 2025-12